Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects (good and bad) of the combination of
ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade) in patients with relapsed/refractory
mantle cell lymphoma.
Zevalin is a monoclonal antibody that is combined with a radioactive substance and given with
another monoclonal antibody called rituximab (Rituxan). It works by attaching to cancer cells
and releasing radiation to damage those cells. Both Zevalin and Rituxan are given in this
study, along with Velcade.